Literature DB >> 9369378

Repaglinide, glibenclamide and glimepiride administration to normal and hereditarily diabetic rats.

L Ladrière1, F Malaisse-Lagae, J Fuhlendorff, W J Malaisse.   

Abstract

Repaglinide (1 microg/g body wt), glibenclamide (10 microg/g) or glimepiride (10 microg/g) were administered orally to either fed or overnight fasted normal rats and hereditarily diabetic animals (GK rats). In both fed and starved normal rats, repaglinide provoked a greater and more rapid increase in plasma insulin concentration and an earlier fall in glycemia than those observed after administration of the hypoglycemic sulfonylureas. Likewise, in fed GK rats, the plasma insulin concentration was already increased by 30.0 +/- 1.6% 15 min after administration of repaglinide, whilst a sizeable insulinotropic action of the sulfonylureas was only recorded at much later times. Except for a lower glycemia at the 240th min of the test, there was little to distinguish, in starved GK rats, between control experiments including the oral administration of the solution of carboxymethylcellulose used as vehicle and the experiments conducted with the antidiabetic agents. Several converging observations indicated that glimepiride stimulated insulin release more promptly than glibenclamide. It is proposed that advantage can be taken from these vastly different time-courses of the hormonal and metabolic response to distinct hypoglycemic agents to optimize the control of glucose homeostasis in non-insulin-dependent diabetic subjects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9369378     DOI: 10.1016/s0014-2999(97)01212-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

Review 1.  Repaglinide: a review of its use in type 2 diabetes mellitus.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2012-01-22       Impact factor: 9.546

Review 2.  Repaglinide.

Authors:  J A Balfour; D Faulds
Journal:  Drugs Aging       Date:  1998-08       Impact factor: 3.923

Review 3.  Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.

Authors:  C R Culy; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  The role of sulphonylureas in the management of type 2 diabetes mellitus.

Authors:  Marc Rendell
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Effect of metabolic inhibition on glimepiride block of native and cloned cardiac sarcolemmal K(ATP) channels.

Authors:  C L Lawrence; R D Rainbow; N W Davies; N B Standen
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

6.  Effect of repaglinide on insulin secretion in islets from rats infused for two days with a hypertonic solution of D-glucose.

Authors:  K Louchami; L Ladrière; H Jijakli; W J Malaisse
Journal:  Endocrine       Date:  1998-06       Impact factor: 3.925

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.